A lot of screening is done for STIs. In fact it is a common diagnostic test.
I understand we might see sales of the enteric pathogen test in Europe this year, which will be a nice step forward. Its also exciting the process for FDA approval has begun.
I agree this stock is under the radar. Bioshares haven't even covered it, virtually since the company listed. As I said previously there's a shift to molecular methods underway at present and we're really well placed.
GSS Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)